Home
Product
Protein
Active Protein
Other
Recombinant Human Ephrin type-A receptor 2 (EPHA2F), partial (Active)

Recombinant Human Ephrin type-A receptor 2 (EPHA2F), partial (Active)

In Stock

Code: CSB-MP007722HUd7

Rate （N/A）
Review （0）

Size:

20ug100ug1mg

US$108

Quantity:

Express system: Mammalian cell

Species: Homo sapiens (Human)

Tag Info: C-terminal 10xHis-tagged

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Abbreviation

Recombinant Human EPHA2 protein, partial (Active)

Purity

Greater than 95% as determined by SDS-PAGE.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

①Measured by its binding ability in a functional ELISA. Immobilized Human EPHA2 at 2 μg/mL can bind Anti-EPHA2 recombinant antibody (CSB-RA007722MA1HU). The EC50 is 36.24-50.53 ng/mL.②Measured by its binding ability in a functional ELISA. Immobilized Human EPHA2 at 2 μg/mL can bind Human EFNA1 (CSB-MP007460HU). The EC50 is 5.859-7.758 ng/mL.

Target Names

EPHA2

Uniprot NO.

P29317

Alternative Names

Ephrin type-A receptor 2; EC:2.7.10.1; Epithelial cell kinase; Tyrosine-protein kinase receptor ECKEPHA2; ECK

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

24-534aa

Target Protein Sequence

AQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCKETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGGEEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGN
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.

Mol. Weight

57.7 kDa

Protein Length

Partial

Tag Info

C-terminal 10xHis-tagged
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.

Buffer

Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4

Storage

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Lead Time

3-7 business days
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Shelf Life

The shelf life is related to many factors, storage state, storage temperature and the stability of the product itself. Generally, the shelf life of lyophilized form is 6 months at -20°C/-80°C from the date of receipt.

Troubleshooting and FAQs

Protein FAQs

Datasheet & COA

Please contact us to get it.

Images

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human EPHA2 at 2 μg/ml can bind Anti-EPHA2 recombinant antibody (CSB-RA007722MA1HU). The EC₅₀ is 36.24-50.53 ng/mL.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human EPHA2 at 2 μg/ml can bind Human EFNA1 (CSB-MP007460HU). The EC₅₀ is 5.859-7.758 ng/mL.
Greater than 95% as determined by SDS-PAGE.
Greater than 95% as determined by SEC-HPLC.

Description

EPHA2 mediates contact-dependent cell signaling in tumor progression and angiogenesis, making it a priority target for therapeutic antibody and small-molecule inhibitor development. This mammalian-expressed construct spanning residues 24–534 captures the complete extracellular domain, ensuring native glycosylation and disulfide bonding critical for physiological ligand recognition. Functional ELISA validation demonstrates robust binding to its cognate ligand EFNA1 with an EC50 of 5.859–7.758 ng/mL, confirming that the receptor retains the conformational integrity required for ligand-binding assays, competitive inhibition screens, and therapeutic antibody epitope mapping. The protein also binds an anti-EPHA2 recombinant antibody with an EC50 of 36.24–50.53 ng/mL, supporting its use as a positive control in antibody validation workflows and blocking antibody screening campaigns. Purity exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg align with standards expected in surface plasmon resonance and bio-layer interferometry experiments for affinity characterization.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

Gene References into Functions

Binding of Candida albicans to ephrin type-A receptor 2 (EphA2) on oral epithelial cells activates signal transducer and activator of transcription 3 and mitogen-activated protein kinase signalling, and is required for induction of a proinflammatory and antifungal response. EphA2 (-/-) mice have impaired inflammatory responses and reduced interleukin-17 signalling during oropharyngeal candidiasis. PMID:29133884
EphA2 has a role in extracellular vesicle secretion from senescent cells that promote cancer cell proliferation PMID:28585531
Combination of polymorphisms in the NOD2, IL17RA, EPHA2 and KALRN genes could play a significant role in the development of sarcoidosis by maintaining a chronic pro-inflammatory status in macrophages PMID:29554915
Phosphorylation of RCP at Ser(435) by Lemur tyrosine kinase-3 (LMTK3) and of EphA2 at Ser(897) by Akt are both necessary to promote Rab14-dependent (and Rab11-independent) trafficking of EphA2 which generates cell:cell repulsion events that drive tumour cells apart. PMID:28294115
EphA2 SAM domain inhibits kinase activity by reducing receptor oligomerization. PMID:28338017
miR-141 inhibits glioma neovascularization by controlling EphA2 expression. PMID:29901110
when overexpressed, EphA2 induces ERK activation through its tyrosine kinase activity, leading to S897 phosphorylation and promotion of glioblastoma cell proliferation. PMID:29626472
findings suggested inhibition of HDACs-EphA2 signaling axis with WW437 alone or in combination with other agents may be a promising therapeutic strategy for advanced breast cancer. PMID:29759486
High EPHA2 expression is associated with epithelial-mesenchymal transition in gastric cancer. PMID:29273006
Ligand-independent activation of EphA2 was triggered by VEGF released from CAF-CM. PMID:29948146
EphA2-mediates glutaminolysis through YAP/TAZ activation in HER2-positive breast cancer and may serve as potential therapeutic targets in patients. PMID:29208682
Data indicate a promising role for EPH receptor A2 (EPHA2) as a target in antibody treatments for melanoma. PMID:29848674
These observations demonstrate that EphA2 affects the sensitivity to oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells. PMID:28624791
High erythropoietin-producing hepatocellular carcinoma receptor A (EphA) 1, 2, and 4 expression levels were significantly related to recurrence. PMID:29491103
the dimer structures of human EphA2 receptor depend on the lipid environment, which we show is linked to the location of the structural motifs in the dimer interface, thereby establishing that both sequence and membrane composition modulate the complete energy landscape of membrane-bound proteins. PMID:27559086
data suggest that novel germ-line (blood) and somatic (lens) coding SNVs in EPHA2 that are predicted to be functionally deleterious occur in adults over 50 years of age PMID:29267365
The YSA peptide stabilizes the EphA2 dimer. PMID:27281300
A 3D structural model of a mutant with a novel 39-AA polypeptide at the C-terminus had partial disorder in the acquired C-terminal tail and a few residues making an alpha-helix and 2 short beta-strands. 2 peptides comprising the whole C-terminus and its predicted helical region, respectively, did not interact with EphA2-Sam or Ship2-Sam. The C-terminus should not wrap the EphA2-Sam End-Helix interface or affect Sam dom... PMID:28602916
EphA2 expression is enriched in the basal-like breast cancer molecular subtype and correlates with poor recurrence-free survival in human triple-negative breast cancers PMID:28581527
The SAM domain inhibits EphA2-ligands interactions in the plasma membrane. PMID:27776928
These findings show that radiation induces S897 EphA2 phosphorylation, an event associated with increased cell survival. Therefore, targeting pathways that mediate EphA2 S897 phosphorylation may be a beneficial strategy to reduce radioresistance. PMID:28705041
Our findings broaden the spectrum of causative mutations in EPHA2 gene for congenital cataract and suggest that WES is an efficient strategy to scan variants in known causative genes for genetically heterogeneous diseases. PMID:27380975
Afadin (AFDN), a cytoskeletal and junction-associated protein, was present in 2D and 3D keratinocyte cultures, and validated as a so-far-unknown EphA2-interacting protein. PMID:27815408
EphA2, a member of the large family of Ephrin receptor tyrosine kinases, is a functional signaling receptor for progranulin. PMID:27903606
both EphA2 and EphB4 show potential as target for image-guided colorectal cancer surgery, but EphB4 seems to have the best characteristics with respect to tumor/normal mucosa distribution PMID:28165374
EphA2 is a key downstream target of the MEK/ERK/RSK signaling pathway in the regulation of glioblastoma cell proliferation. PMID:27132626
possible involvement of membrane-type 1 matrix metalloproteinase processing of erythropoietin-producing hepatocellular receptor-2in invasiveness of cutaneous cutaneous squamous cell carcinoma PMID:27056569
cells with Lipoplatin. The combined effects of siRNA-EphA2 and Lipoplatin were determined. We report that silencing EphA2 significantly enhanced the cellular sensitivity of lung tumor and MPM cells to Lipoplatin and maybe a potential therapy for lung cancer. PMID:27438907
Data show that the EphA2 ectodomain harbors a membrane-binding motif in the FN2 domain which preferentially interacts with anionic lipids. PMID:26724997
Data show that microRNA miR-141 is down-regulated in hepatocellular carcinoma (HCC) tissues and it is negatively correlated with erythropoietin-producing hepatocellular receptor A2 (EphA2) expression. PMID:27412940
Nuclear expression of EphA2 in this series of large tumours was significantly associated with an increased rate of metastasis. On the other hand, cytoplasmic localisation was associated with a better prognosis. As there was no correlation between EphA2 expression and angiogenesis, the mature vasculature or VM, EphA2 appears to become less important in the advanced stages of the disease. PMID:26854480
These data suggest that miR-26b enhances the radiosensitivity of 97H hepatocellular cancer cells by targeting EphA2 protein. PMID:26843134
EphA2 protein may be used as a new marker for the prognosis of clear cell renal cell carcinoma. PMID:26722543
Mis-localization of two of the mutant proteins in epithelial cells suggests that some disease-causing mutations in EPHA2 likely affect lens epithelial cell homeostasis and contribute to cataract. PMID:26900323
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer PMID:26283684
Based on these findings we propose that EphA2 promotes cell adhesion by an unknown signaling pathway that largely depends on the extracellular region of EphA2 and the activation of outside-in integrin signaling PMID:26565750
The present study does not support a major role of EphA2 in cataractogenesis in an Estonian population. PMID:24673449
Overexpression of Ephrin A2 receptor in cancer stromal cells is a prognostic factor for the relapse of gastric cancer. PMID:24908114
Role for EPHA2 in the maintenance of cell survival of TKI-resistant, EGFR-mutant lung cancer and indicate that EPHA2 may serve as a useful therapeutic target in TKI-resistant tumors. PMID:26744526
Overexpression of miR-26b dramatically inhibited the proliferation, invasion, and migration of hepatocellular carcinoma cells by targeting EphA2. PMID:26191168
EphA2/FAK/RhoA signaling pathway plays a critical role in the malignant cellular behavior of renal cell carcinoma PMID:26177500
EphA2 forms dimers in the plasma membrane of HEK293T cells in the absence of ephrin ligand binding, suggesting that the current seeding mechanism model of EphA2 activation is incomplete. PMID:26363067
peptide fragments of Odin-Sam1 interacting with EphA2-Sam PMID:26120079
we show that EphA2 is an undiscovered important surface and intracellular signaling receptor that is crucial for chlamydial infection and development. PMID:25906164
SLAP controls SRC/EPHA2/AKT signalling via destabilization of the SRC substrate and receptor tyrosine kinase EPHA2 PMID:24457997
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype PMID:25542447
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma PMID:25542448
EPHA2 expression is correlated with poor survival specifically in basal-like breast cancer and its expression is repressed by miR-200a through direct interaction with the 3'UTR of EPHA2. PMID:26088362
Data show that ligand-binding domain of receptor tyrosine kinase EphA2 is cleaved frequently by the membrane metalloproteinase MT1-MMP. PMID:26130649
Results show that MiR-26a is overexpressed in patients with atherosclerosis and its role in the disease is mediated by its target EphA2 via a mechanism involving the p38 MAPK/VEGF pathway. PMID:25613580

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein. Cell projection, ruffle membrane; Single-pass type I membrane protein. Cell projection, lamellipodium membrane; Single-pass type I membrane protein. Cell junction, focal adhesion.

Protein Families

Protein kinase superfamily, Tyr protein kinase family, Ephrin receptor subfamily

Tissue Specificity

Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary.

Database Links

HGNC: 3386

UNIGENE: Hs.171596

KEGG: hsa:1969

STRING: 9606.ENSP00000351209

OMIM: 116600

Promotions